Verastem, Inc. plans conference to unveil progress on KRAS G12D trial

Verastem, Inc. plans conference to unveil progress on KRAS G12D trial
Verastem unveils KRAS trial update

Verastem, Inc. announced its plan to host an investor conference call and webcast to present progress and updated preliminary data from its Phase 1/2 TARGET-D 101 study.

The trial focuses on the oral KRAS G12D (ON/OFF) inhibitor VS-7375, assessing both dose escalation and expansion, evaluating the drug as a monotherapy and in combination regimens. The company aims to provide deeper insights into its ongoing research efforts for this promising candidate. Details are being clarified.

Verastem previously secured U.S. FDA Fast Track status for its novel KRAS G12D inhibitor targeting non-small cell lung cancer patients. The company’s development efforts for this candidate have centered on advancing clinical evaluation. Further updates on trial progress and data are expected in the upcoming investor call.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.